Swiss OK for NWBT's DCVax-Brain
USA-based Northwest Biotherapeutics says it has received authorization from the Swiss Institute of Public Health to launch its cancer treatment DCVax-Brain in Switzerland, making it the first therapeutic vaccine to gain regulatory approval for this indication.
DCVax platform applicable to "most cancers"
NWBT explained that its DCVax technology platform has the potential to treat a wide range of cancers. Vaccines developed using the system mobilize a wide-ranging immune response that is both innate and adaptive, rather than employing a single immunostimulatory agent to elicit a specific reaction. The firm added that its approach does not cause the problematic toxicities that are associated with other cancer therapies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze